Understanding heart artery disease using biomarkers and imaging in Oxford

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study combines blood tests with multiple imaging methods to explore the biology and imaging features of coronary artery disease and myocardial injury. It looks at upstream plaque behavior in the arteries and how it translates to heart muscle damage using intracoronary imaging, MRI, CT, and invasive physiology. Participants are adults with evidence of myocardial injury or those planned for coronary angiography with PCI, under non-emergency or emergency settings. The study seeks to identify multimodal biomarkers and imaging signals associated with disease progression and injury patterns. Lead sponsorship is from the University of Oxford and the Oxford Heart Centre at John Radcliffe Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.

Exclusion Criteria:

* Patients in whom safety or clinical concerns preclude participation.
* Anaemia (Hb \<9).
* Pregnant or breast feeding females.

Additional exclusion criteria for patients undergoing MRI

* claustrophobia which limits / prevents participants from remaining in MRI scanner.
* patients who cannot lie flat on the scan table.
* patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.
* patients with known allergy to medium of contrast (gadolinium)

Additional exclusion criteria for patients undergoing coronary CT angiography

* patients with a known allergy to iodinated contrast media
* eGFR\< 30 ml/min (stage 3-5 renal disease)

Where it's running

• Oxford Heart Centre, John Radcliffe Hospital
  Oxford, United Kingdom Recruiting

Study contacts

• Principal investigator: Keith M Channon — University of Oxford
• Study coordinator: Keith M Channon, MD
• Email: keith.channon@cardiov.ox.ac.uk
• Phone: +44 1865 287581

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GPIIb/IIIa PET/CT Imaging for Thrombi in the Brain and Body

  This study tests an imaging tracer called 18F/68Ga-GP1 to see if it safely helps identify thrombi in adults who might have them.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07813559

• Biomarker t6A for Early Detection of Bacterial Infection in Newborns

  A bi-center study tests whether the t6A biomarker can quickly detect early-onset sepsis in newborns who need blood tests.

  Recruiting Salzburger Landeskliniken · Salzburg and 1 other locations · NCT07670624

• Isometric resistance exercise for atherosclerosis in hypertension

  This study tests whether isometric resistance exercise, like wall squats, can improve markers of atherosclerosis in adults with high blood pressure.

  Recruiting Chinese University of Hong Kong · Shatin · NCT07665034

• IVUS-based ultrasound method to measure blood flow through narrowed coronary arteries

  This study tests whether an IVUS-derived software can quickly tell if a narrowed coronary artery is reducing blood flow in adults having coronary angiography, without using pressure wires or vasodilator drugs.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07446023

• How moderate wine drinking affects healthy aging through post-meal extracellular vesicles

  This test will see if a single serving of red or white wine changes circulating extracellular vesicles in healthy adults aged 35–65.

  Recruiting University of Seville · Seville, Sevilla · NCT07361887

• ABP-745 to reduce atherosclerotic plaque in people with ASCVD

  This trial will test whether ABP-745 reduces atherosclerotic plaque over 52 weeks in adults (18–75) with ASCVD who are already taking oral lipid-lowering therapy.

  Recruiting Phase 2 Atom Therapeutics Co., Ltd · Beverly Hills, California and 32 other locations · NCT07303777

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.